Abstract
There were many hurdles in the drug discovery of cathepsin K inhibitors such as species differences not only in bone metabolism but also in amino acid sequences in the critical site of the target enzyme, discrepancies between PK/PD due to unique tissue distribution of the inhibitor affecting both efficacy and side effects originated from a characteristic intracellular or tissue distribution of some classes of compounds. The value of this new therapeutic approach over the launched indirect competitors should be further clarified from the efficacy and side effect point of view. The cathepsin K inhibitor drug discovery was initiated based on a strong and osteoclast-specific expression of this enzyme. However, the tissues and cells expressing cathepsin K have been expanding as the investigation on pathological conditions progressed with respect to side effects as well as new possible indications.
Keywords: Cathepsin K inhibitors, Species differences, PK/PD, On- and Off-target Side Effects, Osteoporosis, Bone resorption, Osteoclasts
Current Topics in Medicinal Chemistry
Title: Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Volume: 10 Issue: 7
Author(s): Motohiko Kometani, Kazuhiko Nonomura, Takashi Tomoo and Satoru Niwa
Affiliation:
Keywords: Cathepsin K inhibitors, Species differences, PK/PD, On- and Off-target Side Effects, Osteoporosis, Bone resorption, Osteoclasts
Abstract: There were many hurdles in the drug discovery of cathepsin K inhibitors such as species differences not only in bone metabolism but also in amino acid sequences in the critical site of the target enzyme, discrepancies between PK/PD due to unique tissue distribution of the inhibitor affecting both efficacy and side effects originated from a characteristic intracellular or tissue distribution of some classes of compounds. The value of this new therapeutic approach over the launched indirect competitors should be further clarified from the efficacy and side effect point of view. The cathepsin K inhibitor drug discovery was initiated based on a strong and osteoclast-specific expression of this enzyme. However, the tissues and cells expressing cathepsin K have been expanding as the investigation on pathological conditions progressed with respect to side effects as well as new possible indications.
Export Options
About this article
Cite this article as:
Kometani Motohiko, Nonomura Kazuhiko, Tomoo Takashi and Niwa Satoru, Hurdles in the Drug Discovery of Cathepsin K Inhibitors, Current Topics in Medicinal Chemistry 2010; 10 (7) . https://dx.doi.org/10.2174/156802610791113478
DOI https://dx.doi.org/10.2174/156802610791113478 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nicotinic Acetylcholine Receptor Agonists: A Potential New Class of Analgesics
Current Topics in Medicinal Chemistry C5a, a Therapeutic Target in Sepsis
Recent Patents on Anti-Infective Drug Discovery Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Dexmedetomidine: A Review of its Use for the Management of Pain, Agitation, and Delirium in the Intensive Care Unit
Current Pharmaceutical Design Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry Endotoxin Recognition Molecules MD-2 and Toll-like Receptor 4 as Potential Targets for Therapeutic Intervention of Endotoxin Shock
Current Drug Targets - Inflammation & Allergy Action of the Aqueous Extract of Sesamum Radiatum Schum. & Tonn.(Pedaliaceae) on the Cardiovascular System of Mammalians: Hypotensive Effect
Current Bioactive Compounds Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Current Neuropharmacology Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Is Relief from Diabetes Just a Breath Away … ?
Current Drug Delivery Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Current Drug Delivery Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Organic Toxins as Tools to Understand Ion Channel Mechanisms and Structure
Current Topics in Medicinal Chemistry Relevance of Neuropeptide Y (NPY) in Psychiatry
Current Topics in Medicinal Chemistry